Although the company will continue to pursue “higher-risk, high reward” drug candidates such as pegilodecakin, these will be a smaller part of the portfolio in the future, said Chief Scientific Officer Daniel Skovronsky. “I encourage parents of teens in all states to talk to their teens and discourage them from sexting because even when sexting […]

جستجو در سایت

درحال بارگذاری ...
بستن
مقایسه